RetiSpec
Noninvasive Eye Scan to Detect Alzheimer's Disease
Company Overview
Snapshot
Founded in June 2016 by Roy Kirshon, RetiSpec operates with 11–50 employees. The company has raised $13.55M across 4 funding rounds from 4 investors. In July 2024, RetiSpec closed a funding round to advance the commercialization of its AI-driven eye test for Alzheimer's disease detection.
Business overview
RetiSpec is a medical imaging company focused on developing a noninvasive tool for the early detection of Alzheimer's disease biomarkers in the eye. The company aims to enable widespread early detection through accessible and scalable screening, utilizing patented hyperspectral imagery in synergy with machine learning. This technology allows for rapid, simple, and cost-effective identification of Alzheimer's biomarkers years before clinical symptoms emerge, serving the healthcare and life sciences sectors, particularly providers.
Strategic signal
In July 2024, RetiSpec secured funding to advance the commercialization of its AI-driven eye test for Alzheimer's disease. This development signals a significant step towards bringing its diagnostic technology to market, offering investors and innovation teams a clear indication of the company's immediate focus on scaling its solution and potentially transforming early Alzheimer's detection.
Log in to access full profile ›Company Intelligence Q&A
- What is RetiSpec's primary focus?
- RetiSpec is developing a medical imaging tool for the early detection of Alzheimer's disease biomarkers through a noninvasive eye scan.
- When was RetiSpec founded?
- RetiSpec was founded in June 2016.
- What was a significant funding event for RetiSpec?
- In July 2024, RetiSpec closed a funding round to advance the commercialization of its AI-driven eye test for the detection of Alzheimer's disease. iGan Partners led this round, with participation from Gentex Corporation.
- Which organization collaborated with RetiSpec to commercialize its technology?
- In October 2018, the University of Minnesota collaborated with RetiSpec to commercialize its technology for the early detection of Alzheimer's disease.
- What grant did RetiSpec receive in 2022?
- In May 2022, RetiSpec and Toronto Memory Program were awarded a grant to launch an innovative early detection program for Alzheimer's in Toronto, Canada.